title: Class D β-lactamases: a reappraisal after five decades.
abstract: Despite 70 years of clinical use, β-lactam antibiotics still remain at the forefront of antimicrobial chemotherapy. The major challenge to these life-saving therapeutics is the presence of bacterial enzymes (i.e., β-lactamases) that can hydrolyze the β-lactam bond and inactivate the antibiotic. These enzymes can be grouped into four classes (A-D). Among the most genetically diverse are the class D β-lactamases. In this class are β-lactamases that can inactivate the entire spectrum of β-lactam antibiotics (penicillins, cephalosporins, and carbapenems). Class D β-lactamases are mostly found in Gram-negative bacteria such as Pseudomonas aeruginosa , Escherichia coli , Proteus mirabilis , and Acinetobacter baumannii . The active-sites of class D β-lactamases contain an unusual N-carboxylated lysine post-translational modification. A strongly hydrophobic active-site helps create the conditions that allow the lysine to combine with CO2, and the resulting carbamate is stabilized by a number of hydrogen bonds. The carboxy-lysine plays a symmetric role in the reaction, serving as a general base to activate the serine nucleophile in the acylation reaction, and the deacylating water in the second step. There are more than 250 class D β-lactamases described, and the full set of variants shows remarkable diversity with regard to substrate binding and turnover. Narrow-spectrum variants are most effective against the earliest generation penicillins and cephalosporins such as ampicillin and cephalothin. Extended-spectrum variants (also known as extended-spectrum β-lactamases, ESBLs) pose a more dangerous clinical threat as they possess a small number of substitutions that allow them to bind and hydrolyze later generation cephalosporins that contain bulkier side-chain constituents (e.g., cefotaxime, ceftazidime, and cefepime). Mutations that permit this versatility seem to cluster in the area surrounding an active-site tryptophan resulting in a widened active-site to accommodate the oxyimino side-chains of these cephalosporins. More concerning are the class D β-lactamases that hydrolyze clinically important carbapenem β-lactam drugs (e.g., imipenem). Whereas carbapenems irreversibly acylate and inhibit narrow-spectrum β-lactamases, class D carbapenemases are able to recruit and activate a deacylating water. The rotational orientation of the C6 hydroxyethyl group found on all carbapenem antibiotics likely plays a role in whether the deacylating water is effective or not. Inhibition of class D β-lactamases is a current challenge. Commercially available inhibitors that are active against other classes of β-lactamases are ineffective against class D enzymes. On the horizon are several compounds, consisting of both β-lactam derivatives and non-β-lactams, that have the potential of providing novel leads to design new mechanism-based inactivators that are effective against the class D enzymes. Several act synergistically when given in combination with a β-lactam antibiotic, and others show a unique mechanism of inhibition that is distinct from the traditional β-lactamase inhibitors. These studies will bolster structure-based inhibitor design efforts to facilitate the optimization and development of these compounds as class D inactivators.
authors.affiliation: Department of Chemistry, Grand Valley State University , Allendale, Michigan 49401, United States.
authors.forename: David A
authors.initials: DA
authors.lastname: Leonard
authors.forename: Robert A
authors.initials: RA
authors.lastname: Bonomo
authors.forename: Rachel A
authors.initials: RA
authors.lastname: Powers
mesh_terms: D002384:Catalysis; D020134:Catalytic Domain; D006090:Gram-Negative Bacteria / Q000201:enzymology*; D008958:Models, Molecular; D001618:beta-Lactamases / Q000378:metabolism*
chemical_list: D001618:beta-Lactamases
references.citation: Biochemistry. 1998 Feb 24;37(8):2622-8
references.pmid: 9485412
references.citation: J Antibiot (Tokyo). 2000 Oct;53(10):1022-7
references.pmid: 11132946
references.citation: J Antimicrob Chemother. 1995 Sep;36(3):585-6
references.pmid: 8830026
references.citation: Antimicrob Agents Chemother. 2013 Jan;57(1):130-6
references.pmid: 23070171
references.citation: J Antimicrob Chemother. 1999 Mar;43(3):339-44
references.pmid: 10223588
references.citation: Science. 2009 Feb 27;323(5918):1215-8
references.pmid: 19251630
references.citation: Antimicrob Agents Chemother. 1998 Jan;42(1):1-17
references.pmid: 9449253
references.citation: Biochemistry. 2012 Apr 10;51(14):3143-50
references.pmid: 22429123
references.citation: Proc Natl Acad Sci U S A. 2007 Mar 27;104(13):5354-9
references.pmid: 17374723
references.citation: Biochemistry. 2010 Aug 17;49(32):6887-95
references.pmid: 20695527
references.citation: Antimicrob Agents Chemother. 2006 Dec;50(12):4114-23
references.pmid: 17000742
references.citation: J Mol Biol. 2011 Mar 4;406(4):583-94
references.pmid: 21215758
references.citation: Antimicrob Agents Chemother. 2010 Jan;54(1):24-38
references.pmid: 19721065
references.citation: J Am Chem Soc. 2010 Sep 29;132(38):13320-31
references.pmid: 20822105
references.citation: Biochemistry. 2009 Jul 7;48(26):6136-45
references.pmid: 19485421
references.citation: Biochemistry. 2003 Nov 11;42(44):12835-43
references.pmid: 14596597
references.citation: Drug Resist Updat. 2000 Apr;3(2):109-125
references.pmid: 11498375
references.citation: J Biol Chem. 2009 Jan 9;284(2):945-53
references.pmid: 18955486
references.citation: Bioorg Med Chem Lett. 2011 Jul 15;21(14):4363-5
references.pmid: 21664132
references.citation: Proc Natl Acad Sci U S A. 2001 Dec 4;98(25):14280-5
references.pmid: 11724923
references.citation: J Biol Chem. 2011 Sep 9;286(36):31466-72
references.pmid: 21775440
references.citation: Biochem J. 2008 Mar 15;410(3):455-62
references.pmid: 18031291
references.citation: Chem Rev. 1998 Apr 2;98(2):549-562
references.pmid: 11848907
references.citation: Johns Hopkins Med J. 1982 Dec;151(6):302-12
references.pmid: 6757513
references.citation: J Antimicrob Chemother. 2010 Jul;65(7):1428-32
references.pmid: 20478991
references.citation: Biochemistry. 2010 May 4;49(17):3766-73
references.pmid: 20353175
references.citation: Biochemistry. 1982 Jun 8;21(12):2857-62
references.pmid: 7049231
references.citation: Antimicrob Agents Chemother. 2010 Dec;54(12):5021-7
references.pmid: 20921306
references.citation: Biochemistry. 2008 Apr 1;47(13):4094-101
references.pmid: 18324783
references.citation: Clin Microbiol Infect. 2008 Jan;14 Suppl 1:42-52
references.pmid: 18154527
references.citation: J Am Chem Soc. 2002 Mar 20;124(11):2461-5
references.pmid: 11890794
references.citation: Antimicrob Agents Chemother. 2010 May;54(5):2167-74
references.pmid: 20145076
references.citation: Antimicrob Agents Chemother. 1995 Jan;39(1):227-31
references.pmid: 7695311
references.citation: Clin Microbiol Rev. 2010 Jan;23(1):160-201
references.pmid: 20065329
references.citation: Nature. 1992 Oct 22;359(6397):700-5
references.pmid: 1436034
references.citation: Antimicrob Agents Chemother. 2011 Jan;55(1):390-4
references.pmid: 21041502
references.citation: J Antimicrob Chemother. 2012 Jul;67(7):1597-606
references.pmid: 22499996
references.citation: Proc Natl Acad Sci U S A. 2011 Nov 8;108(45):18424-9
references.pmid: 22042844
references.citation: J Biol Chem. 2012 Mar 9;287(11):8232-41
references.pmid: 22262858
references.citation: Biochemistry. 1999 Mar 16;38(11):3293-301
references.pmid: 10079072
references.citation: Antimicrob Agents Chemother. 2001 Dec;45(12):3509-16
references.pmid: 11709332
references.citation: Antimicrob Agents Chemother. 2003 Sep;47(9):2859-63
references.pmid: 12936985
references.citation: Biochemistry. 2005 Dec 13;44(49):16121-9
references.pmid: 16331972
references.citation: J Antimicrob Chemother. 2011 Aug;66(8):1745-50
references.pmid: 21665906
references.citation: Antimicrob Agents Chemother. 2008 Sep;52(9):3135-43
references.pmid: 18559643
references.citation: Biochem J. 1991 May 1;275 ( Pt 3):793-5
references.pmid: 1903928
references.citation: J Biol Chem. 2003 May 16;278(20):18419-25
references.pmid: 12591921
references.citation: J Biol Chem. 2011 Oct 28;286(43):37292-303
references.pmid: 21880707
references.citation: Antimicrob Agents Chemother. 2009 Apr;53(4):1698-700
references.pmid: 19188386
references.citation: Chem Biol. 2009 May 29;16(5):540-7
references.pmid: 19477418
references.citation: J Am Chem Soc. 2008 Sep 24;130(38):12656-62
references.pmid: 18761444
references.citation: Chem Rev. 2005 Feb;105(2):395-424
references.pmid: 15700950
references.citation: Curr Pharm Des. 1999 Nov;5(11):865-79
references.pmid: 10539993
references.citation: Antimicrob Agents Chemother. 1997 Oct;41(10):2188-95
references.pmid: 9333046
references.citation: Protein Sci. 2003 Jan;12(1):82-91
references.pmid: 12493831
references.citation: Biochem J. 1983 Jan 1;209(1):229-33
references.pmid: 6405733
references.citation: Antimicrob Agents Chemother. 2010 Apr;54(4):1414-24
references.pmid: 20086146
references.citation: Biochem J. 2010 Dec 15;432(3):495-504
references.pmid: 21108605
references.citation: Biochemistry. 2000 May 2;39(17):4971-81
references.pmid: 10819961
references.citation: J Antimicrob Chemother. 2010 Feb;65(2):364-5
references.pmid: 20008045
references.citation: Antimicrob Agents Chemother. 1994 Apr;38(4):767-72
references.pmid: 8031044
references.citation: Nat Struct Biol. 2000 Oct;7(10):918-25
references.pmid: 11017203
references.citation: Biochemistry. 2009 Dec 1;48(47):11252-63
references.pmid: 19860471
references.citation: Bioorg Med Chem Lett. 2010 Apr 15;20(8):2622-4
references.pmid: 20299220
references.citation: Bioorg Med Chem Lett. 2009 Jul 1;19(13):3593-7
references.pmid: 19467869
references.citation: Biochem J. 1994 Nov 1;303 ( Pt 3):825-30
references.pmid: 7980451
references.citation: Biochemistry. 2009 Dec 22;48(50):11840-7
references.pmid: 19919101
references.citation: Structure. 2000 Dec 15;8(12):1289-98
references.pmid: 11188693
references.citation: J Mol Biol. 2001 Jul 20;310(4):859-74
references.pmid: 11453693